Cancer Treatment News and Research

RSS

Radiation breakthrough to treat breast cancer patients in one day arrives at CTCA

A radiation breakthrough to treat breast cancer patients in one day, as opposed to the current average of six weeks, has arrived at Cancer Treatment Centers of America(R) (CTCA) in Philadelphia. CTCA will become the first in the country to offer this treatment option using the Novac7 technology from Rome, Italy.

19 Nov 2009

New source of information can help prescribers and patients in understanding anticipated side effects of treatments

In clinical trials for cancer, it is standard for clinicians rather than patients to report adverse symptom side effects from treatments, such as nausea and fatigue. At present, patient self-reporting, although important, is not a well studied source of this information.

18 Nov 2009

ThromboGenics and BioInvent International present phase I results of novel anti-cancer monoclonal antibody

ThromboGenics NV and BioInvent International AB today announced positive results from a Phase I trial of their novel anti-cancer monoclonal antibody TB-403 in patients with advanced solid tumours. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, U.S. TB-403 was well tolerated with no reported dose limiting toxicity. These positive data support progression of TB-403 and further development.

17 Nov 2009

HDAC inhibitors: New therapy for treating breast cancer

A powerful new breast cancer treatment could result from packaging one of the newer drugs that inhibits cancer's hallmark wild growth with another that blocks a primordial survival technique in which the cancer cell eats part of itself, researchers say.

17 Nov 2009

Erbitux recognized as one of the major clinical cancer advances of 2009

The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with 1st-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

16 Nov 2009

NIH offers $1.6 million, three-year grant to Prism Clinical Imaging

Prism Clinical Imaging, Inc., in collaboration with investigators at The Medical College of Wisconsin in Milwaukee, has received a $1.6 million, three-year grant from the National Institutes of Health (NIH) to develop and clinically validate advanced medical imaging software that aids the diagnosis and treatment of patients with brain cancer.

16 Nov 2009

Findings on the use of Traumeel S in children with mucositis undergoing SCT presented

New research findings presented today at the Society for Integrative Oncology's (SIO) Sixth International Conference in New York show promise in assessing the efficacy and safety of complementary and alternative medicine (CAM) using traditional research methods.

13 Nov 2009

Breast cancer patients who undergo fertility preservation need not delay treatment

A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion.

13 Nov 2009

RERF awarded $9.7M to study the effects of atomic bomb radiation and aging on the human immune system

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded nearly $9.7 million over five years to the Radiation Effects Research Foundation (RERF), Japan, to study the effects of atomic bomb radiation and aging on the human immune system.

13 Nov 2009

Predictive power of Champions Biotechnology's Biomerk Tumorgraft platform to be presented

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has announced that two of its studies regarding its application in oncology drug development and personalized medicine have been selected for a poster and oral presentation at the upcoming AACR-EORTC conference in Boston.

12 Nov 2009

Researchers identify a new mechanism that inhibits the formation of new blood vessels

Researchers at Uppsala University, in collaboration with colleagues in Sweden and abroad, have identified an entirely new mechanism by which a specific protein in the body inhibits formation of new blood vessels. Inhibiting the formation of new blood vessels is an important aspect of, for example, cancer treatment. The study is published in the November issue of the journal Molecular Cancer Research.

12 Nov 2009

Cancer screening methods are not perfect: Experts

In a recent New York Times article, the American Cancer Society (ACS) ignited a major controversy over the benefits of cancer screening, specifically with regards to their breast and prostate cancer guidelines. In the article, Dr. Otis Brawley, chief medical officer of the ACS, responded to a study in the current issue of the Journal of the American Medical Association.

11 Nov 2009

Researchers find link between two genes involved in cancer formation in humans

Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment.

11 Nov 2009

Potential new drug for lung cancer eliminates tumors in mice

A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.

11 Nov 2009

SAVI reaches a major milestone in breast brachytherapy

This month marks three years since physicians began offering SAVI™ radiation treatment as part of breast conservation therapy for early-stage breast cancer – a major milestone in breast brachytherapy.

10 Nov 2009

Prepubertal boys with cancer can bank on their testicular tissue for preserving fertility

For parents of children with cancer, the hopeful news is that pediatric survival rates have steadily improved for decades. Among the bad news-treatments that enable survival often cause infertility.

10 Nov 2009

Decision Resources forecasts sales of HER2-targeting agents to grow by 3.3% per year

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment.

9 Nov 2009

Transatlantic task force to address antibiotic resistance established, experts welcome initiative

Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.

7 Nov 2009

Experts applaud the EU Presidency for establishing a transatlantic task force to address antibiotic resistance

7 Nov 2009

American Shared Hospital Services reports financial results for the third quarter of 2009

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the third quarter and first nine months of 2009.

5 Nov 2009

Cancer Treatment News and Research

Radiation breakthrough to treat breast cancer patients in one day arrives at CTCA

New source of information can help prescribers and patients in understanding anticipated side effects of treatments

ThromboGenics and BioInvent International present phase I results of novel anti-cancer monoclonal antibody

HDAC inhibitors: New therapy for treating breast cancer

Erbitux recognized as one of the major clinical cancer advances of 2009

NIH offers $1.6 million, three-year grant to Prism Clinical Imaging

Findings on the use of Traumeel S in children with mucositis undergoing SCT presented

Breast cancer patients who undergo fertility preservation need not delay treatment

RERF awarded $9.7M to study the effects of atomic bomb radiation and aging on the human immune system

Predictive power of Champions Biotechnology's Biomerk Tumorgraft platform to be presented

Researchers identify a new mechanism that inhibits the formation of new blood vessels

Cancer screening methods are not perfect: Experts

Researchers find link between two genes involved in cancer formation in humans

Potential new drug for lung cancer eliminates tumors in mice

SAVI reaches a major milestone in breast brachytherapy

Prepubertal boys with cancer can bank on their testicular tissue for preserving fertility

Decision Resources forecasts sales of HER2-targeting agents to grow by 3.3% per year

Transatlantic task force to address antibiotic resistance established, experts welcome initiative

Experts applaud the EU Presidency for establishing a transatlantic task force to address antibiotic resistance

American Shared Hospital Services reports financial results for the third quarter of 2009

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News